Bohua Bio (06955.HK): Injection solution of Abicipar submitted for marketing authorization in Brazil

Zhiyuan Finance APP reported that Boan Bio (06955.HK) announced that the marketing authorization application for its Abicipar intraocular injection solution (BA9101) has been submitted to the Brazilian National Health Surveillance Agency (ANVISA) for the treatment of adult new vascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME).